B · Normal
On November 13, Novo Nordisk submitted a marketing application for etavopivat to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Etavopivat reduced vaso-occlusive crises by 27% and delayed the first vaso-occlusive crisis by approximately 4 months.
medicine 🕐 2026-11-13 19:03
#medicine
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[The State Food and Drug Administration deploys and optimizes the management of 11-13 17:03 [The world's first topical pan-JAK inhibitor for adults with moderate to severe 11-13 16:13 [Hubei releases the province’s first biomedical industry mutual insurance body] 11-13 14:42 [U.S. FDA terminates rapid drug review program] November 12th, the U.S. Food and 11-12 19:50 On November 12, sources and documents showed that the U.S. FDA had shelved the f 11-12 19:01 On November 12, Eli Lilly’s stock price rose 3% before the market opened as Chin 11-12 17:55

Comments

0/500
Captcha (click to refresh)
No comments yet